Baxter International BAX Healthcare Systems & Technologies — Currency translation and other
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments.
The official record: Baxter International’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's healthcare systems & technologies — currency translation and other.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Baxter International's healthcare systems & technologies — currency translation and other?
- Baxter International (BAX) reported healthcare systems & technologies — currency translation and other of $5.5M in Q4 2025.
- How has Baxter International's healthcare systems & technologies — currency translation and other changed year-over-year?
- Baxter International's healthcare systems & technologies — currency translation and other increased by 257.1% year-over-year, from -$3.5M to $5.5M.
- What is the long-term trend for Baxter International's healthcare systems & technologies — currency translation and other?
- Over 3 years (2022 to 2025), Baxter International's healthcare systems & technologies — currency translation and other has grown at a -14.3% compound annual growth rate (CAGR), from -$35M to $22M.
- What does healthcare systems & technologies — currency translation and other mean?
- The net financial impact of foreign currency exchange rate changes and miscellaneous non-operating items on segment earnings.
- How do you interpret healthcare systems & technologies — currency translation and other?
- A large negative value indicates headwinds from a strengthening reporting currency, while a positive value suggests a tailwind.
- How does healthcare systems & technologies — currency translation and other compare across companies?
- Commonly reported as 'Foreign Exchange Impact' or 'FX Effect' in segment reconciliations across multinational medical device firms.